Novartis | NVS - Current Liabilities


Novartis reported $31.37B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bausch Health Companies USD 4.54B 14M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Drreddys Laboratories INR 167.57B 165.8B Mar/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
J&J USD 55.46B 562M Sep/2026
Merck USD 27.73B 786M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Pacira USD 122.01M 13.22M Jun/2026
Perrigo USD 1.05B 57.2M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Phibro Animal Health USD 316.47M 34.6M Jun/2026
Prestige Brands USD 153.81M 32.88M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Supernus Pharmaceuticals USD 347.38M 26.55M Jun/2026
Zoetis USD 2.06B 8M Jun/2026